可溶性B7-H4在恶性淋巴瘤中的表达及临床意义

目的:探讨恶性淋巴瘤(ML)患者血清中可溶性B7-H4(sB7-H4)的水平及临床意义。方法:收集ML患者71例(初发组59例,复发组12例)及健康体检者40名的血清标本,采用ELISA法检测血清中sB7-H4的水平;用免疫组织化学方法检测30例淋巴瘤组织及10例淋巴细胞反应性增生组织中B7-H4的表达情况。结果:ML患者血清中sB7-H4的表达水平在非霍奇金淋巴瘤和霍奇金淋巴瘤患者均高于健康对照组(P<0.01),非霍奇金淋巴瘤组亦高于霍奇金淋巴瘤组(P<0.05);复发组患者血清中sB7-H4的表达水平低于初发组(P<0.05),但明显高于健康对照组(P<0.01);免疫组化结果显示,ML组织中B7-H4的阳性表达率高于淋巴细胞反应性增生组织(P<0.05)。结论:sB7-H4在ML患者血清中高表达,为淋巴瘤的辅助诊断、预后提供了一个新的肿瘤标志物。

Expression of the soluble B7-H4 in malignant lymphoma and its clinical significance

Objective:To investigate the expression of serum soluble B7-H4(sB7-H4)in patients with malignant lymphoma(ML),and its clinical significance. Methods:The serum levels of sB7-H4 in 71 cases with ML ( including 59 primary patients and 12 recurrent patients) and 40 healthy people were detected by ELISA. The protein expressions of sB7-H4 in 30 cases of lymphoma tissue and 10 cases of lymphocyte hyperplasia tissue were detected by immunohistochemistry. Results:The serum levels of sB7-H4 in patients with non-Hodgkin lymphoma(NHL) and Hodgkin lymphoma(HL) were singnificantly higher than that in healthy control group(P<0. 01). The serum level of B7-H4 in NHL group was higher than that in HL group(P<0. 05). The serum level of sB7-H4 in primary group was significantly lower than that in recurrent group,and was significantly higher than that in healthy control group(P <0. 01). The immunohistochemistry results showed that the positive rate of sB7-H4 in lymphoma tissue was higher than that in lymphocyte hyperplasia tissue(P<0. 05). Conclusions:The serum expression of sB7-H4 in ML patients is high,which can provide a new tumor marker in the accessory diagnosis and prognosis of lymphoma.